Omega-3 Supplementation Dry Eye Randomized Trial: What the Evidence Says

Quick Answer

Omega-3 Supplementation Dry Eye Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 observational study, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Animal studies have demonstrated that omega-3 fatty acids may decrease glaucoma risk through multiple mechanisms, including lowering IOP, regulating ocular blood flow, providing neuroprotection, and mitigating oxidative stress and inflammation.Clinical studies have also reported an association between omega-3 supplementation and decreases in IOP. [Pan Ssu-Yu (2026); evidence level 3]
• Therefore, cohort studies are warranted to investigate the potential long-term benefits of omega-3 supplementation in reducing glaucoma risk. [Pan Ssu-Yu (2026); evidence level 3]
• In particular, the estimated prevalence of DED increased to 61.0% globally and 56.7% in Asia during the COVID-19 pandemic, markedly higher than the levels prior to the pandemic, possibly due to the proliferation of remote work and online education. [Liu Jiaxiang (2026); evidence level 4]
• Additional contributing factors include incomplete blinking-often associated with prolonged screen use-and direct damage to the corneal epithelial glycocalyx. [Liu Jiaxiang (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For omega-3 supplementation dry eye randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Pan Ssu-Yu (2026). Relationship Between Omega-3 Fatty Acids and Glaucoma Risk in Patients With Dry Eye Disease: A Multinational Retrospective Cohort Study. DOI: 10.1167/tvst.15.6.2. PMCID: PMC13235759. PMID: 42223316. License: https://creativecommons.org/licenses/by-nc-nd/4.0/. https://pmc.ncbi.nlm.nih.gov/articles/PMC13235759/
• Liu Jiaxiang (2026). Advances in Pharmacotherapy and Physiotherapy for Dry Eye Disease: Molecular Mechanisms and Future Directions—A Narrative Literature Review. DOI: 10.3390/ijms27094024. PMCID: PMC13163669. PMID: 42123603. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13163669/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.